There’s a few common payment models used by patient recruitment firms. The agency model where the client will pay a fee for the service. Any associated costs – such as advertising spend – are also paid by the client. The main risk here is that there may be no patients recruited.

The ‘pay per patient’ model is based on a fee per consenting trial participant. The risk here is taken by the patient recruitment firm for any ad spend.

And the ‘pay per lead’ model – where the firm is compensated per patient lead referred into the system. This model tends to be more widely open to abuse, with low quality leads still attracting a fee, whether they become trial participants or not. So my main recommendation is to use the ‘pay per patient’ model, or the agency model if it better fits your circumstances.

You may also like

Biotech C-suites Should keep Patient Recruitment in Mind from the Outset
In biotech, a strong C-suite isn’t just about job titles - it’s about covering every part of the journey from discovery to delivery. Including being prepared to tackle one of the biggest ...
Key C-suite Roles for Biotech Success - The Chief Patient Recruitment Officer (CPRO)
While biotech companies have built C-suites with scientific, medical, financial, operational, and business expertise, a critical function has remained conspicuously absent - addressing one ...
Key C-suite Roles for Biotech Success - The Chief Business Officer (CBO)
The Chief Business Officer leads external strategy - licensing deals, identifying pharma partnerships, and developing long-term growth planning and market positioning strategies that ...